Get Boston vs Los Angeles baseball betting preview, spread and over/under insights for their matchup on June 2.

Boston Scientific has pulled global sales of, and is no longer seeking FDA approval for, its Acurate neo2 and Acurate Prime aortic valve systems. In a May 28 Securities and Exchange Commission filing, ...

The company also shared more details of its exit from the TAVR market and the impact of FDA layoffs on product review times.

Boston Scientific’s retreat from selling its ACURATE heart valves and halting FDA approval efforts created mild ripples in ...

Boston Scientific has discontinued global sales of its Acurate neo2 and Acurate Prime transcatheter aortic valve replacement ...

Boston Scientific Corp. reported the latest setback in its transcatheter aortic valve replacement (TAVR) aspirations with the ...

Boston Scientific will eliminate jobs after discontinuing global sales of its Acurate aortic valve replacement systems that ...

Boston Scientific ends global sales of ACURATE valves and halts FDA pursuit, citing rising regulatory burdens; expects to ...

Boston Scientific said it would halt worldwide sales of its Acurate devices due to “increased clinical and regulatory ...

Shares of Boston Scientific Corporation (BSX) traded 1% lower on Wednesday afternoon after the company announced that it is ...

Boston Scientific is pulling its latest transcatheter aortic heart valve platform from the worldwide market and said it will ...

The explanation for why the valve failed is too little, too late: Boston Scientific ended global sales of the device ...